COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset

被引:87
|
作者
Larsson, Karin [1 ]
Kock, Anna [2 ]
Idborg, Helena [1 ]
Henriksson, Marie Arsenian [3 ]
Martinsson, Tommy [4 ]
Johnsen, John I. [2 ]
Korotkova, Marina [1 ]
Kogner, Per [2 ]
Jakobsson, Per-Johan [1 ,5 ]
机构
[1] Karolinska Inst, Dept Med, Rheumatol Unit, SE-17176 Stockholm, Sweden
[2] Karolinska Inst, Astrid Lindgren Childrens Hosp, Dept Womens & Childrens Hlth, Childhood Canc Res Unit, SE-17176 Stockholm, Sweden
[3] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden
[4] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Clin Genet, SE-40530 Gothenburg, Sweden
[5] Karolinska Univ Hosp, Rheumatol Clin, SE-17176 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
mPGES-1; PGE2; neuroblastoma; tumor microenvironment; cancer-associated fibroblasts; CANCER-ASSOCIATED FIBROBLASTS; PROSTAGLANDIN-E SYNTHASE-1; TUMOR PROGRESSION; IN-VIVO; GROWTH; EXPRESSION; E-2; CELLS; INDUCTION; CYCLOOXYGENASE-2;
D O I
10.1073/pnas.1424355112
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The majority of solid tumors are presented with an inflammatory microenvironment. Proinflammatory lipid mediators including prostaglandin E-2 (PGE(2)) contribute to the establishment of inflammation and have been linked to tumor growth and aggressiveness. Here we show that high-risk neuroblastoma with deletion of chromosome 11q represents an inflammatory subset of neuroblastomas. Analysis of enzymes involved in the production of proinflammatory lipid mediators showed that 11q-deleted neuroblastoma tumors express high levels of microsomal prostaglandin E synthase-1 (mPGES-1) and elevated levels of PGE2. High mPGES-1 expression also corresponded to poor survival of neuroblastoma patients. Investigation of the tumor microenvironment showed high infiltration of tumor-promoting macrophages with high expression of the M2-polarization markers CD163 and CD206. mPGES-1-expressing cells in tumors from different subtypes of neuroblastoma showed differential expression of one or several cancer-associated fibroblast markers such as vimentin, fibroblast activation protein a, a smooth muscle actin, and PDGF receptor beta. Importantly, inhibition of PGE2 production with diclofenac, a nonselective COX inhibitor, resulted in reduced tumor growth in an in vivo model of 11q-deleted neuroblastoma. Collectively, these results suggest that PGE2 is involved in the tumor microenvironment of specific neuroblastoma subgroups and indicate that therapeutic strategies using existing anti-inflammatory drugs in combination with current treatment should be considered for certain neuroblastomas.
引用
收藏
页码:8070 / 8075
页数:6
相关论文
共 50 条
  • [11] Production of Inflammatory Cytokines Is Regulated by mPGES-1-Dependent PGE2 in T Cells
    Maseda, Damian
    Johnson, Elizabeth
    Crofford, Leslie
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S49 - S49
  • [12] COX-2/mPGES-1/PGE2 cascade activation mediates uric acid-induced mesangial cell proliferation
    Li, Shuzhen
    Sun, Zhenzhen
    Zhang, Yue
    Ruan, Yuan
    Chen, Qiuxia
    Gong, Wei
    Yu, Jing
    Xia, Weiwei
    He, John Ci-Jiang
    Huang, Songming
    Zhang, Aihua
    Ding, Guixia
    Jia, Zhanjun
    ONCOTARGET, 2017, 8 (06) : 10185 - 10198
  • [13] Regulation of calcitonin gene-related peptide expression through the COX-2/mPGES-1/PGE2 pathway in the infrapatellar fat pad in knee osteoarthritis
    Aikawa, Jun
    Uchida, Kentaro
    Takano, Shotaro
    Inoue, Gen
    Iwase, Dai
    Miyagi, Masayuki
    Mukai, Manabu
    Shoji, Shintaro
    Sekiguchi, Hiroyuki
    Takaso, Masashi
    LIPIDS IN HEALTH AND DISEASE, 2018, 17
  • [14] GPx2 counteracts PGE2 production by dampening COX-2 and mPGES-1 expression in human colon cancer cells
    Banning, Antje
    Florian, Simone
    Deubel, Stefanie
    Thalmann, Sophie
    Mueller-Schmehl, Katrin
    Jacobasch, Gisela
    Brigelius-Flohe, Regina
    ANTIOXIDANTS & REDOX SIGNALING, 2008, 10 (09) : 1491 - 1500
  • [15] Regulation of calcitonin gene-related peptide expression through the COX-2/mPGES-1/PGE2 pathway in the infrapatellar fat pad in knee osteoarthritis
    Jun Aikawa
    Kentaro Uchida
    Shotaro Takano
    Gen Inoue
    Dai Iwase
    Masayuki Miyagi
    Manabu Mukai
    Shintaro Shoji
    Hiroyuki Sekiguchi
    Masashi Takaso
    Lipids in Health and Disease, 17
  • [16] Targeting mPGES-1 by a Combinatorial Approach: Identification of the Aminobenzothiazole Scaffold to Suppress PGE2 Levels
    Chini, Maria G.
    Giordano, Assunta
    Potenza, Marianna
    Terracciano, Stefania
    Fischer, Katrin
    Vaccaro, Maria C.
    Colarusso, Ester
    Bruno, Ines
    Riccio, Raffaele
    Koeberle, Andreas
    Werz, Oliver
    Bifulco, Giuseppe
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (05): : 783 - 789
  • [17] The non COX-2 inhibitor methyleelecoxib (DMC) inhibits PGE2 production by influencing mPGES-1 activity and expression in HeLa cells
    Wobst, I.
    Schiffmann, S.
    Maier, T. J.
    Janssen, A.
    Schmidt, R.
    Angioni, C.
    Geisslinger, G.
    Goersch, S.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 375 : 28 - 29
  • [18] Hypoxia-inducible factor-2 is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer
    Xue, Xiang
    Shah, Yatrik M.
    CARCINOGENESIS, 2013, 34 (01) : 163 - 169
  • [19] Dihydroartemisinin inhibits indoxyl sulfate (IS)-promoted cell cycle progression in mesangial cells by targeting COX-2/mPGES-1/PGE2 cascade
    Mungun, Harr-Keshauve
    Li, Shuzhen
    Zhang, Yue
    Huang, Songming
    Jia, Zhanjun
    Ding, Guixia
    Zhang, Aihua
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (02): : 422 - 431
  • [20] Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity
    Kahnt, Astrid Stefanie
    Roersch, Florian
    Diehl, Olaf
    Hofmann, Bettina
    Lehmann, Christoph
    Steinbrink, Svenja Dorothea
    Angioni, Carlo
    Geisslinger, Gerd
    Groesch, Sabine
    Steinhilber, Dieter
    Maier, Thorsten Juergen
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (02) : 286 - 296